Insurers are starting to cover internet, not just telehealth; Biogen's disappointing financial outlook for 2022

Federal and state health programs are exploring new ways to cover not just telehealth visits, but internet access that makes them possible. ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ 

Sponsored by      As internet access limits telehealth's reach, insurers are starting to cover the bill By Katie Palmer Hyacinth Empinado/STAT Federal and state health programs are exploring new ways to cover not just telehealth visits, but internet access that makes them possible. Read More STAT+: A scientific pioneer finds herself on the sidelines of the race in xenotransplantation By Megan Molteni Kayana Szymczak for STAT Luhan Yang, the intensely driven superstar whose work kicked the xeno field up a few dozen notches, hit a series of unforeseen obstacles. Read More STAT+: With Alzheimer's drug sales weak, Biogen offers a disappointing financial outlook for 2022 By Adam Feuerstein and Damian Garde Ruby Wallau for STAT Sales of Aduhelm, Biogen’s treatment for Alzheimer’s disease, continued to underperform expectations in the fourth quarter. Read More Sponsor content by AMERICAN CANCER SOCIETY Over 2 million people are missing out on the care they need. Close the Medicaid coverage gap. Increased access to health coverage through Medicaid expansion has resulted in earlier stage cancer diagnosis and improved survival rates. More than 2 million people — the majority of whom are people of color — are missing out on the care they need because of hurdles to affordable, comprehensive health coverage in non-expansion states. It's time for all Americans to have equitable access to care. Congress, close the coverage gap to remove hurdles to cancer care. 'The numbers are pretty appalling': Asian scientists rarely awarded top scientific prizes By Usha Lee McFarling Courtesy Noah Berger A new analysis finds that Asian scientists, heavily represented in American biomedical research, are rarely granted prestigious prizes. Read More STAT+: Lawmakers grill key FDA official over controversial Alzheimer's drug approval By Nicholas Florko Alex Wong/Getty Images One of the FDA's highest ranking drug regulators set out to testify on three looming funding bills. But lawmakers grilled her about Aduhelm. Read More STAT+: As the telemedicine industry rapidly expands, the Biden administration takes a closer look at who's benefiting By Casey Ross Adobe The Biden administration's efforts come as digital health companies raise huge sums on thin evidence so far that they're improving outcomes. Read More STAT+: Key lawmaker: ARPA-H won't be part of NIH By Lev Facher Chip Somodevilla/Getty Images Rep. Anna Eshoo told STAT that ARPA-H, the moonshot agency meant to “end cancer as we know it,” won’t be housed within the NIH. Read More STAT+: Such a deal! Covid-19 therapies appear cost-effective … for now By Ed Silverman Merck "The drugs are fairly priced for the benefits that we can perceive," said Steve Pearson of the Institute for Clinical and Economic Review. Read More Listen: Califf's sudden jeopardy, the quest for a PCSK9 pill, & Covid vaccines for kids By Damian Garde and Meg Tirrell and Adam Feuerstein STAT's Nicholas Florko joins us to explain why Robert Califf, once a shoo-in to be the next FDA commissioner, is suddenly in serious jeopardy. Read More Thursday, February 3, 2022       1 Exchange Pl, Suite 201, Boston, MA 02109 ©2022, All Rights Reserved. I no longer wish to receive STAT emails Update Email Preferences | Contact Us | View In Browser